To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

In vivo Detection of Alzh… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

In vivo Detection of Alzheimer's Disease.

Review article
Authors Antoine Leuzy
Kerstin Heurling
Nicholas Ashton
Michael Schöll
Eduardo R Zimmer
Published in The Yale journal of biology and medicine
Volume 91
Issue 3
Pages 291-300
ISSN 1551-4056
Publication year 2018
Published at Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Pages 291-300
Language en
Keywords Alzheimer Disease, diagnosis, Amyloid beta-Peptides, metabolism, Animals, Biomarkers, metabolism, Diagnostic Imaging, Humans
Subject categories Medical Biotechnology


Recent revisions to the diagnostic criteria for Alzheimer's disease (AD) incorporated conceptual advances in the field. Specifically, AD is now recognized to encompass a continuum, spanning from preclinical (accruing brain pathology in the absence of symptoms) through symptomatic predementia (prodromal AD, mild cognitive impairment) and dementia phases. The role of biological markers (biomarkers) of both the underlying molecular pathologies and related neurodegenerative changes has also been acknowledged. In this abridged review, we provide an overview of fluid (cerebrospinal fluid and blood) and molecular imaging-based biomarkers used within the field and discuss the potential role of computer driven artificial intelligence approaches for both the early and accurate identification of AD and as a tool for population enrichment in clinical trials testing candidate disease modifying therapies.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?